Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Total Non-Current Liabilities (2019 - 2024)

Lipocine (LPCN) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $1.6 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Total Non-Current Liabilities fell 29.61% year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Sep 2024, down 29.61%, and an annual FY2023 reading of $2.6 million, up 55.8% over the prior year.
  • Total Non-Current Liabilities was $1.6 million for Q3 2024 at Lipocine, down from $1.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $8.9 million in Q3 2020 and bottomed at -$35.5 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $2.0 million, with a median of $2.2 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities tumbled 72.56% in 2022, then surged 105.15% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $8.8 million in 2020, then plummeted by 30.81% to $6.1 million in 2021, then crashed by 72.56% to $1.7 million in 2022, then surged by 55.8% to $2.6 million in 2023, then crashed by 39.66% to $1.6 million in 2024.
  • Business Quant data shows Total Non-Current Liabilities for LPCN at $1.6 million in Q3 2024, $1.7 million in Q2 2024, and $1.4 million in Q1 2024.